155,915 Shares in Gritstone bio, Inc. (NASDAQ:GRTS) Bought by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. acquired a new position in Gritstone bio, Inc. (NASDAQ:GRTS) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 155,915 shares of the company’s stock, valued at approximately $96,000. Point72 Asia Singapore Pte. Ltd. owned approximately 0.14% of Gritstone bio at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Klingman & Associates LLC bought a new position in shares of Gritstone bio in the 1st quarter worth about $89,000. BNP Paribas Financial Markets lifted its holdings in shares of Gritstone bio by 85.2% during the first quarter. BNP Paribas Financial Markets now owns 46,237 shares of the company’s stock valued at $119,000 after purchasing an additional 21,271 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in shares of Gritstone bio during the first quarter valued at approximately $636,000. Vanguard Group Inc. boosted its position in shares of Gritstone bio by 7.2% in the 1st quarter. Vanguard Group Inc. now owns 4,733,791 shares of the company’s stock worth $12,166,000 after purchasing an additional 317,499 shares in the last quarter. Finally, Lazard Asset Management LLC purchased a new stake in shares of Gritstone bio in the 1st quarter worth approximately $70,000. Hedge funds and other institutional investors own 48.46% of the company’s stock.

Gritstone bio Price Performance

Shares of GRTS opened at $0.61 on Friday. Gritstone bio, Inc. has a twelve month low of $0.42 and a twelve month high of $3.33. The company has a market capitalization of $65.71 million, a P/E ratio of -0.49 and a beta of 0.47. The firm has a 50 day moving average of $0.54 and a 200 day moving average of $0.87. The company has a quick ratio of 2.54, a current ratio of 2.54 and a debt-to-equity ratio of 1.83.

Gritstone bio (NASDAQ:GRTS) last posted its earnings results on Tuesday, August 13th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.12. The business had revenue of $0.92 million during the quarter, compared to analyst estimates of $2.77 million. Gritstone bio had a negative return on equity of 328.51% and a negative net margin of 910.50%. As a group, equities research analysts anticipate that Gritstone bio, Inc. will post -0.88 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on GRTS shares. HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of Gritstone bio in a research note on Thursday, August 15th. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price target on shares of Gritstone bio in a research report on Monday, August 5th.

Gritstone bio Profile

Gritstone bio, Inc, a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors.